387 related articles for article (PubMed ID: 23982524)
1. The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma.
Kaufman HL; Kirkwood JM; Hodi FS; Agarwala S; Amatruda T; Bines SD; Clark JI; Curti B; Ernstoff MS; Gajewski T; Gonzalez R; Hyde LJ; Lawson D; Lotze M; Lutzky J; Margolin K; McDermott DF; Morton D; Pavlick A; Richards JM; Sharfman W; Sondak VK; Sosman J; Steel S; Tarhini A; Thompson JA; Titze J; Urba W; White R; Atkins MB
Nat Rev Clin Oncol; 2013 Oct; 10(10):588-98. PubMed ID: 23982524
[TBL] [Abstract][Full Text] [Related]
2. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia.
Boyiadzis M; Bishop MR; Abonour R; Anderson KC; Ansell SM; Avigan D; Barbarotta L; Barrett AJ; Van Besien K; Bergsagel PL; Borrello I; Brody J; Brufsky J; Cairo M; Chari A; Cohen A; Cortes J; Forman SJ; Friedberg JW; Fuchs EJ; Gore SD; Jagannath S; Kahl BS; Kline J; Kochenderfer JN; Kwak LW; Levy R; de Lima M; Litzow MR; Mahindra A; Miller J; Munshi NC; Orlowski RZ; Pagel JM; Porter DL; Russell SJ; Schwartz K; Shipp MA; Siegel D; Stone RM; Tallman MS; Timmerman JM; Van Rhee F; Waller EK; Welsh A; Werner M; Wiernik PH; Dhodapkar MV
J Immunother Cancer; 2016; 4():90. PubMed ID: 28018601
[TBL] [Abstract][Full Text] [Related]
3. An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0.
Sullivan RJ; Atkins MB; Kirkwood JM; Agarwala SS; Clark JI; Ernstoff MS; Fecher L; Gajewski TF; Gastman B; Lawson DH; Lutzky J; McDermott DF; Margolin KA; Mehnert JM; Pavlick AC; Richards JM; Rubin KM; Sharfman W; Silverstein S; Slingluff CL; Sondak VK; Tarhini AA; Thompson JA; Urba WJ; White RL; Whitman ED; Hodi FS; Kaufman HL
J Immunother Cancer; 2018 May; 6(1):44. PubMed ID: 29848375
[TBL] [Abstract][Full Text] [Related]
4. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma.
McNeel DG; Bander NH; Beer TM; Drake CG; Fong L; Harrelson S; Kantoff PW; Madan RA; Oh WK; Peace DJ; Petrylak DP; Porterfield H; Sartor O; Shore ND; Slovin SF; Stein MN; Vieweg J; Gulley JL
J Immunother Cancer; 2016; 4():92. PubMed ID: 28031820
[TBL] [Abstract][Full Text] [Related]
5. ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines Committee.
Michielin O; van Akkooi A; Lorigan P; Ascierto PA; Dummer R; Robert C; Arance A; Blank CU; Chiarion Sileni V; Donia M; Faries MB; Gaudy-Marqueste C; Gogas H; Grob JJ; Guckenberger M; Haanen J; Hayes AJ; Hoeller C; Lebbé C; Lugowska I; Mandalà M; Márquez-Rodas I; Nathan P; Neyns B; Olofsson Bagge R; Puig S; Rutkowski P; Schilling B; Sondak VK; Tawbi H; Testori A; Keilholz U
Ann Oncol; 2020 Nov; 31(11):1449-1461. PubMed ID: 32763452
[TBL] [Abstract][Full Text] [Related]
6. ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee.
Keilholz U; Ascierto PA; Dummer R; Robert C; Lorigan P; van Akkooi A; Arance A; Blank CU; Chiarion Sileni V; Donia M; Faries MB; Gaudy-Marqueste C; Gogas H; Grob JJ; Guckenberger M; Haanen J; Hayes AJ; Hoeller C; Lebbé C; Lugowska I; Mandalà M; Márquez-Rodas I; Nathan P; Neyns B; Olofsson Bagge R; Puig S; Rutkowski P; Schilling B; Sondak VK; Tawbi H; Testori A; Michielin O
Ann Oncol; 2020 Nov; 31(11):1435-1448. PubMed ID: 32763453
[TBL] [Abstract][Full Text] [Related]
7. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC).
Brahmer JR; Govindan R; Anders RA; Antonia SJ; Sagorsky S; Davies MJ; Dubinett SM; Ferris A; Gandhi L; Garon EB; Hellmann MD; Hirsch FR; Malik S; Neal JW; Papadimitrakopoulou VA; Rimm DL; Schwartz LH; Sepesi B; Yeap BY; Rizvi NA; Herbst RS
J Immunother Cancer; 2018 Jul; 6(1):75. PubMed ID: 30012210
[TBL] [Abstract][Full Text] [Related]
8. Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma.
Kamat AM; Bellmunt J; Galsky MD; Konety BR; Lamm DL; Langham D; Lee CT; Milowsky MI; O'Donnell MA; O'Donnell PH; Petrylak DP; Sharma P; Skinner EC; Sonpavde G; Taylor JA; Abraham P; Rosenberg JE
J Immunother Cancer; 2017 Aug; 5(1):68. PubMed ID: 28807024
[TBL] [Abstract][Full Text] [Related]
9. [Standards, Options and Recommendations (SOR): clinical practice guidelines for diagnosis, treatment and follow-up of cutaneous melanoma. Fédération Nationale des Centres de Lutte Contre le Cancer].
Négrier S; Fervers B; Bailly C; Beckendorf V; Cupissol D; Doré JF; Dorval T; Garbay JR; Vilmer C
Bull Cancer; 2000 Feb; 87(2):173-82. PubMed ID: 10705288
[TBL] [Abstract][Full Text] [Related]
10. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0.
Pavlick AC; Ariyan CE; Buchbinder EI; Davar D; Gibney GT; Hamid O; Hieken TJ; Izar B; Johnson DB; Kulkarni RP; Luke JJ; Mitchell TC; Mooradian MJ; Rubin KM; Salama AK; Shirai K; Taube JM; Tawbi HA; Tolley JK; Valdueza C; Weiss SA; Wong MK; Sullivan RJ
J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37852736
[TBL] [Abstract][Full Text] [Related]
11. Cancer immunotherapy in special challenging populations: recommendations of the Advisory Committee of Spanish Melanoma Group (GEM).
Gonzalez-Cao M; Puertolas T; Riveiro M; Muñoz-Couselo E; Ortiz C; Paredes R; Podzamczer D; Manzano JL; Molto J; Revollo B; Carrera C; Mateu L; Fancelli S; Espinosa E; Clotet B; Martinez-Picado J; Cerezuela P; Soria A; Marquez I; Mandala M; Berrocal A;
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33782108
[TBL] [Abstract][Full Text] [Related]
12. Controversies in the management of advanced melanoma: "gray" areas amid the "black and blue".
Jarkowski A; Norris L; Trinh VA
Ann Pharmacother; 2014 Nov; 48(11):1456-68. PubMed ID: 25056920
[TBL] [Abstract][Full Text] [Related]
13. NIH Consensus Statement on Management of Hepatitis C: 2002.
NIH Consens State Sci Statements; 2002 Jun 10-12; 19(3):1-46. PubMed ID: 14768714
[TBL] [Abstract][Full Text] [Related]
14. Melanoma, version 2.2013: featured updates to the NCCN guidelines.
Coit DG; Andtbacka R; Anker CJ; Bichakjian CK; Carson WE; Daud A; Dimaio D; Fleming MD; Guild V; Halpern AC; Hodi FS; Kelley MC; Khushalani NI; Kudchadkar RR; Lange JR; Lind A; Martini MC; Olszanski AJ; Pruitt SK; Ross MI; Swetter SM; Tanabe KK; Thompson JA; Trisal V; Urist MM; McMillian N; Ho M;
J Natl Compr Canc Netw; 2013 Apr; 11(4):395-407. PubMed ID: 23584343
[TBL] [Abstract][Full Text] [Related]
15. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
16. [Clinical practice guideline: 2005 update of recommendations for the management of patients with cutaneous melanoma without distant metastases (summary report)].
Négrier S; Saiag P; Guillot B; Verola O; Avril MF; Bailly C; Cupissol D; Dalac S; Danino A; Dreno B; Grob JJ; Leccia MT; Renaud-Vilmer C; Bosquet L; ; ; ; ; ; ; ;
Bull Cancer; 2006 Apr; 93(4):371-84. PubMed ID: 16714227
[TBL] [Abstract][Full Text] [Related]
17. European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2019.
Garbe C; Amaral T; Peris K; Hauschild A; Arenberger P; Bastholt L; Bataille V; Del Marmol V; Dréno B; Fargnoli MC; Grob JJ; Höller C; Kaufmann R; Lallas A; Lebbé C; Malvehy J; Middleton M; Moreno-Ramirez D; Pellacani G; Saiag P; Stratigos AJ; Vieira R; Zalaudek I; Eggermont AMM;
Eur J Cancer; 2020 Feb; 126():159-177. PubMed ID: 31866016
[TBL] [Abstract][Full Text] [Related]
18. Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology.
Alessandrino EP; Amadori S; Barosi G; Cazzola M; Grossi A; Liberato LN; Locatelli F; Marchetti M; Morra E; Rebulla P; Visani G; Tura S;
Haematologica; 2002 Dec; 87(12):1286-306. PubMed ID: 12495903
[TBL] [Abstract][Full Text] [Related]
19. Japanese Dermatological Association Guidelines: Outlines of guidelines for cutaneous melanoma 2019.
Nakamura Y; Asai J; Igaki H; Inozume T; Namikawa K; Hayashi A; Fukushima S; Fujimura T; Ito T; Imafuku K; Tanaka R; Teramoto Y; Minagawa A; Miyagawa T; Miyashita A; Wada M; Koga H; Sugaya M
J Dermatol; 2020 Feb; 47(2):89-103. PubMed ID: 31782186
[TBL] [Abstract][Full Text] [Related]
20. Single-agent interleukin-2 in the treatment of metastatic melanoma.
Petrella T; Quirt I; Verma S; Haynes AE; Charette M; Bak K;
Curr Oncol; 2007 Feb; 14(1):21-6. PubMed ID: 17576460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
